Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmaceutical prospects for RNA interference.

Raymond M Schiffelers1, Martin C Woodle, Puthupparampil Scaria

  • 1Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, PO Box 80082, 3508 TB Utrecht, The Netherlands. Raymond@intradigm.com

Pharmaceutical Research
|February 27, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficiency and immunogenicity of lipid nanoparticle-mediated cardiac mRNA delivery are lipid composition-dependent.

Molecular therapy. Nucleic acids·2026
Same author

Decoding RNA regulation: Challenges and opportunities for RNA-based therapies in Europe.

British journal of clinical pharmacology·2026
Same author

Longitudinal 3D-DCE MRI Assessment of Placental Perfusion Under Reduced Uterine Perfusion Pressure in Pregnant Rats.

NMR in biomedicine·2026
Same author

Magnetic Lipid Nanoparticles for Targeted mRNA Delivery and Enhanced Organ-Specific Expression.

ACS applied materials & interfaces·2026
Same author

Toward <i>In Vivo</i> CAR T Cell Therapy: Perfecting CAR and Lipid Nanoparticle Design.

Nano letters·2026
Same author

Hybrid Extracellular Vesicles for Efficient Loading and Functional Delivery of mRNA.

Journal of extracellular vesicles·2025
Same journal

Leveraging Carnitine-functionalized Lipid Nanocarrier based Targeted Delivery of A1874 PROTAC for Glioblastoma.

Pharmaceutical research·2026
Same journal

Impact of Febrile State on Vancomycin Clearance in Pediatric Patients: Insights From Population Pharmacokinetic Modeling.

Pharmaceutical research·2026
Same journal

Sustained Intra-Articular Delivery of Triple Therapeutics Using a Phase-Transition Phospholipid-Based Gel for Effective Treatment of Gouty Arthritis.

Pharmaceutical research·2026
Same journal

Spray Dried Lysozyme Microspheres: Morphological Evolution and Enzymatic Activity Retention.

Pharmaceutical research·2026
Same journal

Colloidal Stability of Amorphous Nanoparticles in Solution: Impact of Stabilizer.

Pharmaceutical research·2026
Same journal

Impact of Mixing Approach and Bubble Formation on In Situ Forming Implant Properties.

Pharmaceutical research·2026
See all related articles

RNA interference (RNAi) is a powerful gene silencing tool. Recent studies show its potential as a novel therapeutic strategy for diseases, with this review highlighting clinical advancements.

Area of Science:

  • Molecular Biology
  • Genetics
  • Biotechnology

Background:

  • RNA interference (RNAi) is a well-established technique for validating gene function.
  • Emerging research indicates RNAi's capacity to modulate disease progression.
  • This presents RNAi as a promising avenue for novel therapeutic interventions.

Purpose of the Study:

  • To review recent advancements in RNA interference technology.
  • To discuss the progress in translating RNA interference into clinical applications.
  • To evaluate the potential of RNA interference as a therapeutic strategy.

Main Methods:

  • Literature review of recent studies on RNA interference.
  • Analysis of research demonstrating disease-modulating effects of RNAi.

Related Experiment Videos

  • Assessment of clinical trial progress and challenges for RNAi-based therapies.

    • Main Results:

    • RNA interference has demonstrated significant potential in preclinical and clinical studies.
    • Advancements in delivery systems and target specificity are enhancing RNAi efficacy.
    • Several RNAi-based therapies are progressing through clinical trials for various diseases.

    Conclusions:

    • RNA interference is transitioning from a research tool to a viable therapeutic modality.
    • Continued research and development are crucial for overcoming challenges in RNAi clinical utility.
    • RNA interference holds considerable promise for the future of personalized medicine and disease treatment.